11.07.2015 Views

Novel genetic and epigenetic alterations in ... - Ous-research.no

Novel genetic and epigenetic alterations in ... - Ous-research.no

Novel genetic and epigenetic alterations in ... - Ous-research.no

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

DiscussionIn paper IV, our aim was to identify markers <strong>in</strong> MSI-carc<strong>in</strong>omas that carry prog<strong>no</strong>stic<strong>in</strong>formation. This patient group accounts for about 15% of all CRC patients <strong>and</strong> areassociated with an improved disease outcome compared to that of CRC as a whole. Deathfrom cancer can be a crude measurement as risk of relapse from disease is an importantfactor when evaluat<strong>in</strong>g who would benefit from adjuvant chemotherapy. Hence, disease-freesurvival was chosen as cl<strong>in</strong>ical end-po<strong>in</strong>t <strong>in</strong> order to <strong>in</strong>clude both death from cancer <strong>and</strong>relapse.Driver <strong>and</strong> passenger (epi)mutationsMutations <strong>and</strong> epi<strong>genetic</strong> <strong>alterations</strong> are frequent <strong>in</strong> human tumors, but most likely <strong>no</strong>t all<strong>alterations</strong> are important for tumor development. The discrim<strong>in</strong>ation between driver <strong>and</strong>passenger, or byst<strong>and</strong>er, mutations has ga<strong>in</strong>ed <strong>in</strong>creased <strong>in</strong>terest the last decade. The<strong>alterations</strong> which give the cell a growth advantage will be selected, de<strong>no</strong>ted driver mutations,while the background <strong>no</strong>ise of mutations that confer <strong>no</strong> clonal growth advantage are termedpassenger mutations[201]. When screen<strong>in</strong>g large numbers of genes, <strong>and</strong> especially with themodern ultra high throughput systems, this discrim<strong>in</strong>ation is important.Several methods are applied <strong>in</strong> order to separate the passengers from the drivers, most oftenby use of statistical <strong>and</strong> probability calculations. Simplified one can say that if a mutatio<strong>no</strong>ccurs more often than what would be expected by chance, it <strong>in</strong>dicates a positive selectionwhile a more seldom occurrence <strong>in</strong>dicates a negative selection pressure[201-203]. A study bySjöblom <strong>and</strong> co-workers <strong>in</strong>cluded 13023 genes, among which they found over a thous<strong>and</strong> tobe mutated <strong>in</strong> colorectal <strong>and</strong> breast cancer. Among those, only 189 were considered to begenes with impact on tumorigenesis, with an average of 9 mutated genes per colorectalcarc<strong>in</strong>oma[202].The concept of driver <strong>and</strong> passenger mutations is especially important <strong>in</strong> tumors with MSI,or the mutator phe<strong>no</strong>type. The mutability of mo<strong>no</strong>nucleotide repetitions with<strong>in</strong> MSI-tumorsdepends primarily on structural factors. Because of the high background of <strong>genetic</strong> <strong>in</strong>stabilityit is challeng<strong>in</strong>g to establish which of these <strong>alterations</strong> plays a role <strong>in</strong> tumorigenesis. Duval<strong>and</strong> co-workers has suggested two schemes to divide the genes <strong>in</strong>to driver <strong>and</strong> by-st<strong>and</strong>er61

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!